Vumon

(teniposide)

ApprovedSmall molecule

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vumon is one of 73 small molecule programs targeting Adult Acute Lymphoblastic Leukemia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Adult Acute Lymphoblastic LeukemiaActive, not recruiting

Primary Central Nervous System LymphomaRecruiting

Germ Cell TumorRecruiting

Acute Lymphoblastic LeukemiaCompleted

Adult Acute Lymphoblastic LeukemiaApproved

Active, not recruiting

Primary Central Nervous System LymphomaPreclinical

Recruiting

Germ Cell TumorPhase 2

Recruiting

Acute Lymphoblastic LeukemiaApproved

Completed

Competition

Competitive Landscape

163 competitors in Acute Lymphoblastic Leukemia

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

75 2

Adriamycin

Pfizer

Phase 3

40 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

40 4

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

43 5

Fludara

Sanofi

Phase 3

15 6

Iclusig

Takeda

Phase 3

12 7

Medrol

Pfizer

Phase 3

12 8

Cellcept

Roche

Phase 3

11 9

Neoral

Arranon

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Germ Cell Tumor

NCT07188441

Q3 2029

PreclinicalRecruiting

Primary Central Nervous System Lymphoma

NCT07185373

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·UUniversitätsklinikum Hamburg-Eppendorf·N/A·NCT00343369·550 enrolled

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

Completed·GGoethe University·Phase 4·NCT00198991·1,883 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Treatment of High Risk Adult Acute Lymphoblastic Leukemia

Completed·PPETHEMA Foundation·Phase 4·NCT00853008·100 enrolled

Leukemia1 trial

Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia

Unknown status·JJohann Wolfgang Goethe University Hospital·Phase 2·NCT00002531

Lymphoma1 trial

Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1/2·NCT00004916

Mantle Cell Lymphoma1 trial

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004231

4 more indications

Germ Cell Tumor1 trial

Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

Recruiting·CChengcheng Guo·Phase 2·NCT07188441·40 enrolled

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01700946·80 enrolled

Central Nervous System1 trial

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

Unknown status·—·N/A·NCT06048107·20 enrolled

Primary Central Nervous System Lymphoma1 trial

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed Primary Central Nervous System Lymphoma-A Randomized Controlled Trial

Recruiting·HHuashan Hospital·Preclinical·NCT07185373·215 enrolled

Regulatory

FDA Approval Timeline[4]

Jul 14, 1992

VUMON

NDA NDA020119

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for teniposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — teniposide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for teniposide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA020119). U.S. Food & Drug Administration.
[5]
SEC EDGAR — McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Vumon

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2029

Trials by Indication[1]

Acute Lymphoblastic Leukemia2 trials

Adult Acute Lymphoblastic Leukemia1 trial

Leukemia1 trial

Lymphoma1 trial

Mantle Cell Lymphoma1 trial

Germ Cell Tumor1 trial

Precursor B-Cell Acute Lymphoblastic Leukemia1 trial

Central Nervous System1 trial

Primary Central Nervous System Lymphoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News